Keros Therapeutics (KROS) Other Gross PP&E Adjustments (2019 - 2025)
Keros Therapeutics posted quarterly Other Gross PP&E Adjustments of -$15.8 million for Q4 2025, up 19.6% year-on-year from -$13.2 million in Q4 2024, and up 9.66% on a QoQ basis from -$17.5 million in Q3 2025.
Keros Therapeutics (KROS) has 7 years of Other Gross PP&E Adjustments data on file, last reported at -$15.8 million in Q4 2025.
- For the quarter ending Q4 2025, Other Gross PP&E Adjustments rose 19.6% year-over-year to -$15.8 million; the trailing twelve-month figure through Dec 2025 stood at -$15.8 million (up 19.6% YoY), and the FY2025 full-year result was -$15.8 million, up 19.6% from the prior year.
- Other Gross PP&E Adjustments for Q4 2025 stood at -$15.8 million, up from -$17.5 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at $1.1 million in Q4 2021 and bottomed at -$20.3 million in Q4 2023.
- The 5-year median for Other Gross PP&E Adjustments is -$14.8 million (2024), against an average of -$10.4 million.
- The widest annual swing landed in 2021, when Other Gross PP&E Adjustments soared 96.47%; it then tumbled 3405.37% in 2023.
- A 5-year view of Other Gross PP&E Adjustments shows it stood at $1.1 million in 2021, then slumped by 1196.59% to -$12.2 million in 2022, then slumped by 65.96% to -$20.3 million in 2023, then advanced by 3.21% to -$19.6 million in 2024, then increased by 19.6% to -$15.8 million in 2025.
- The last three Other Gross PP&E Adjustments figures came in at -$15.8 million (Q4 2025), -$17.5 million (Q3 2025), and -$18.1 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Keros Therapeutics | 403.85 Mn | 116.45 Mn | - | -15.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -15.78 Mn |
| Dec 31, 2025 | -15.78 Mn |
| Sep 30, 2025 | -17.46 Mn |
| Sep 30, 2025 | -17.46 Mn |
| Jun 30, 2025 | -18.07 Mn |
| Jun 30, 2025 | -18.07 Mn |
| Mar 31, 2025 | -18.67 Mn |
| Mar 31, 2025 | -18.67 Mn |
| Dec 31, 2024 | -19.62 Mn |
| Dec 31, 2024 | -19.62 Mn |
| Sep 30, 2024 | -19.82 Mn |
| Sep 30, 2024 | -19.82 Mn |
| Jun 30, 2024 | -14.65 Mn |
| Jun 30, 2024 | -14.65 Mn |
| Mar 31, 2024 | -15.00 Mn |
| Mar 31, 2024 | -15.00 Mn |
| Dec 31, 2023 | -20.27 Mn |
| Dec 31, 2023 | -20.27 Mn |
| Sep 30, 2023 | -15.67 Mn |
| Sep 30, 2023 | -15.67 Mn |
| Jun 30, 2023 | -16.01 Mn |
| Jun 30, 2023 | -16.01 Mn |
| Mar 31, 2023 | -1.90 Mn |
| Mar 31, 2023 | -1.90 Mn |
| Dec 31, 2022 | -12.22 Mn |
| Dec 31, 2022 | -12.22 Mn |
| Sep 30, 2022 | -447,000.00 |
| Sep 30, 2022 | -447,000.00 |
| Jun 30, 2022 | -658,000.00 |
| Jun 30, 2022 | -658,000.00 |
| Mar 31, 2022 | -864,000.00 |
| Mar 31, 2022 | -864,000.00 |
| Dec 31, 2021 | 1.11 Mn |
| Dec 31, 2021 | 1.11 Mn |
| Sep 30, 2021 | -700,000.00 |
| Sep 30, 2021 | -700,000.00 |
| Jun 30, 2021 | -676,000.00 |
| Jun 30, 2021 | -676,000.00 |
| Mar 31, 2021 | -779,000.00 |
| Mar 31, 2021 | -779,000.00 |
| Dec 31, 2020 | 567,000.00 |
| Dec 31, 2020 | 567,000.00 |
| Sep 30, 2020 | -976,000.00 |
| Sep 30, 2020 | -976,000.00 |
| Jun 30, 2020 | -1.03 Mn |
| Jun 30, 2020 | -1.03 Mn |
| Mar 31, 2020 | -1.12 Mn |
| Mar 31, 2020 | -1.12 Mn |
| Dec 31, 2019 | -44,000.00 |
| Dec 31, 2019 | -44,000.00 |